This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
The product will be commercialized from Unichem's Ghaziabad plant
The company is excluding data from the affected sites to maintain the study's integrity
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Subscribe To Our Newsletter & Stay Updated
